Novel Therapeutic Approach to Preserving or Reversing Pancreatic Islet Beta Cells in Patients With Type 1 Diabetes: A Bayesian Network Meta‐Analysis of Comparative Efficacy

Type 1 diabetes accounts for approximately 10% of all diabetes cases, meaning that a substantial number of patients require lifelong insulin therapy. Although many individuals adapt to the demands of daily injections, they remain vulnerable to hypoglycaemia and long‐term complications, particularly when glycaemic control is suboptimal. These persistent challenges have driven the search for effective treatments that may improve quality of life and potentially induce clinical remission. To address this need, we conducted a Bayesian network meta‐analysis to evaluate the capacity of non‐insulin therapies to preserve pancreatic β‐cell function in type 1 diabetes.

• Publication year

  2026

• Venue

  Diabetes/Metabolism Research Reviews

• Publication date

  2026-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/dmrr.70120PMID 41493044
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies

  2025cited by this paper
• Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial

  2024cited by this paper
• Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient.

  2024cited by this paper
• The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: a systematic review and meta-analysis.

  2024cited by this paper
• Effect of fenofibrate on residual beta cell function in adults and adolescents with newly diagnosed type 1 diabetes: a randomised clinical trial

  2024cited by this paper
• Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial.

  2023cited by this paper
• A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes

  2023cited by this paper
• Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.

  2023influential reference
• A guide and pragmatic considerations for applying GRADE to network meta-analysis

  2023cited by this paper
• Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial

  2023cited by this paper
• Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.

  2023cited by this paper
• Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial

  2023cited by this paper
• C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis.

  2023cited by this paper
• Effect of Liraglutide Treatment on Whole Body Glucose Fluxes in C-peptide Positive Type 1 Diabetes During Hypoglycaemia.

  2022cited by this paper
• Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial

  2022cited by this paper
• Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes.

  2021cited by this paper
• Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial

  2021cited by this paper
• Lack of effect of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: a randomised controlled trial

  2021cited by this paper
• Adipose tissue-derived stromal/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patients

  2021cited by this paper
• Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial

  2021cited by this paper
• A high potency multi‐strain probiotic improves glycemic control in children with new‐onset type 1 diabetes mellitus: A randomized, double‐blind, and placebo‐controlled pilot study

  2021cited by this paper
• Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

  2021cited by this paper
• GRADE guidelines 33: Addressing imprecision in a network meta-analysis.

  2021cited by this paper
• Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial

  2021cited by this paper
• A systematic review and meta‐analysis of interventions to preserve insulin‐secreting β‐cell function in people newly diagnosed with type 1 diabetes: Results from intervention studies aimed at improving glucose control

  2021cited by this paper
• IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes

  2021cited by this paper
• ROB-MEN: a tool to assess risk of bias due to missing evidence in network meta-analysis

  2021cited by this paper
• Ergocalciferol in New-onset Type 1 Diabetes: A Randomized Controlled Trial

  2021cited by this paper
• Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.

  2020cited by this paper
• One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study

  2020cited by this paper
• A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

  2020cited by this paper
• Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes

  2020cited by this paper
• CINeMA: An approach for assessing confidence in the results of a network meta-analysis

  2020cited by this paper
• Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.

  2020cited by this paper
• THE PROMISE AND CHALLENGE OF THERAPEUTIC GENOME EDITING

  2020cited by this paper
• Investigating optimal β‐cell‐preserving treatment in latent autoimmune diabetes in adults: Results from a 21‐month randomized trial

  2019cited by this paper
• A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Alpha-1 Antitrypsin (AAT) (Glassia®) in the Treatment of Recent-Onset Type 1 Diabetes

  2019cited by this paper
• Effect of prebiotic on microbiota, intestinal permeability and glycemic control in children with type 1 diabetes.

  2019cited by this paper
• Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes

  2018cited by this paper
• Registration of systematic reviews in PROSPERO: 30,000 records and counting

  2018cited by this paper
• Verapamil and beta cell function in adults with recent-onset type 1 diabetes

  2018cited by this paper
• [Sustained serum 25-hydroxyvitamin D concentrations for one year with cholecalciferol supplementation improves glycaemic control and slows the decline of residual β cell function in children with type 1 diabetes].

  2018cited by this paper
• Evaluation the Effect of Vitamin D 3 on Glycemic Indices on Iraqi Children with Type 1 DM

  2017cited by this paper
• Association between insulin therapy and quality of life in diabetes

  2017cited by this paper
• Clinical benefits of autologous haematopoietic stem cell transplantation in type 1 diabetes patients.

  2017cited by this paper
• Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes

  2017influential reference
• Does Vitamin D Supplementation Improve Glycaemic Control In Children With Type 1 Diabetes Mellitus? - A Randomized Controlled Trial.

  2017cited by this paper
• High prevalence of diabetes‐specific autoimmunity in first‐degree relatives of Sardinian patients with type 1 diabetes

  2017cited by this paper
• Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes

  2016cited by this paper
• ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

  2016cited by this paper
• Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion

  2015cited by this paper
• Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus - A randomized clinical trial.

  2015cited by this paper
• Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.

  2015cited by this paper
• Efficacy and safety of low‐dose otelixizumab anti‐CD3 monoclonal antibody in preserving C‐peptide secretion in adolescent type 1 diabetes: DEFEND‐2, a randomized, placebo‐controlled, double‐blind, multi‐centre study

  2014cited by this paper
• Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial

  2014cited by this paper
• Evaluating the Quality of Evidence from a Network Meta-Analysis

  2014cited by this paper
• Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes

  2014cited by this paper
• Preserved β-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells

  2014cited by this paper
• Effect of a single autologous cord blood infusion on beta‐cell and immune function in children with new onset type 1 diabetes: a non‐randomized, controlled trial

  2014cited by this paper
• Type 1 diabetes.

  2014cited by this paper
• Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

  2013cited by this paper
• Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.

  2013cited by this paper
• Effect of Pioglitazone on the Course of New-Onset Type 1 Diabetes Mellitus

  2013cited by this paper
• Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8+ T Cells in Type 1 Diabetes

  2013cited by this paper
• A graphical tool for locating inconsistency in network meta-analyses

  2013cited by this paper
• Evidence Synthesis for Decision Making 2

  2013cited by this paper
• Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.

  2013cited by this paper
• Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial

  2013cited by this paper
• Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.

  2013cited by this paper
• Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers

  2013cited by this paper
• Evidence Synthesis for Decision Making 4

  2013cited by this paper
• Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews

  2012cited by this paper
• Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus.

  2012cited by this paper
• GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.

  2012cited by this paper
• The effect of fetal liver-derived cell suspension allotransplantation on patients with diabetes: first year of follow-up.

  2012cited by this paper
• Analysis

  2012cited by this paper
• Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

  2011cited by this paper
• Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

  2011cited by this paper
• Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

  2011cited by this paper
• Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

  2011cited by this paper
• The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial

  2011cited by this paper
• GRADE guidelines: 8. Rating the quality of evidence--indirectness.

  2011cited by this paper
• Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes

  2010cited by this paper
• Checking consistency in mixed treatment comparison meta‐analysis

  2010cited by this paper
• No Effect of the 1α,25-Dihydroxyvitamin D3 on β-Cell Residual Function and Insulin Requirement in Adults With New-Onset Type 1 Diabetes

  2010cited by this paper
• Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

  2010cited by this paper
• No Protective Effect of Calcitriol on β-Cell Function in Recent-Onset Type 1 Diabetes

  2010cited by this paper
• Etanercept Treatment in Children With New-Onset Type 1 Diabetes: Pilot Randomized, Placebo-Controlled, Double-Blind Study

  2009cited by this paper
• Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

  2009cited by this paper
• Etanercept Treatment in Children With New-Onset Type 1 Diabetes

  2009cited by this paper
• No Effect of the Altered Peptide Ligand NBI-6024 on β-Cell Residual Function and Insulin Needs in New-Onset Type 1 Diabetes

  2009cited by this paper
• Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.

  2009cited by this paper
• GAD treatment and insulin secretion in recent-onset type 1 diabetes.

  2008cited by this paper
• Immunotherapeutic agents in type 1 diabetes: a systematic review and meta‐analysis of randomized trials

  2008cited by this paper
• GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

  2008cited by this paper
• Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes.

  2005cited by this paper
• Rosiglitazone combined with insulin preserves islet β cell function in adult‐onset latent autoimmune diabetes (LADA)

  2005cited by this paper
• A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes

  2005cited by this paper
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• Network meta‐analysis for indirect treatment comparisons

  2002cited by this paper

• No citing papers are available for this paper.